A benefit-risk assessment of baclofen in severe spinal spasticity.
about
Operant conditioning of spinal reflexes: from basic science to clinical therapyGABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidenceTargeted neuroplasticity for rehabilitationPharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.Factors associated with oral problems among adults with spinal cord injuryThe comparative study of clinical efficacy and safety of baclofen vs tolperisone in spasticity caused by spinal cord injuryEffects of baclofen on motor units paralysed by chronic cervical spinal cord injury.Baclofen alters gustatory discrimination capabilities and induces a conditioned taste aversion (CTA)Restoring walking after spinal cord injury: operant conditioning of spinal reflexes can helpArbaclofen placarbil decreases reflux with good tolerability in patients with gastroesophageal reflux disease (am j gastroenterol 2010;105:1266-1275)Motoneuron excitability and muscle spasms are regulated by 5-HT2B and 5-HT2C receptor activity.Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptorsIntrathecal baclofen pump for spasticity: an evidence-based analysis.Separate and combined effects of the GABA(B) agonist baclofen and Δ9-THC in humans discriminating Δ9-THC.Operant conditioning of a spinal reflex can improve locomotion after spinal cord injury in humans.Clinical effectiveness of baclofen for the treatment of alcohol dependence: a reviewApplication of high-resolution mass spectrometry to determination of baclofen in a case of fatal intoxicationIntrathecal baclofen therapy for spasticity: A compliance-based study to indicate effectiveness.Oral Baclofen Withdrawal Resulting in Progressive Weakness and Sedation Requiring Intensive Care Admission.Baclofen toxicity in patients with advanced nephropathy: proposal for new labeling.Efficacy and tolerability of baclofen in substance use disorders: a systematic review.Role of Catheter's Position for Final Results in Intrathecal Drug Delivery. Analysis Based on CSF Dynamics and Specific Drugs Profiles.Spasticity - Pathogenesis, prevention and treatment strategies.Spinal cord injury: overview of experimental approaches used to restore locomotor activity.GABA-B(1) receptors are coupled to the ERK1/2 MAP kinase pathway in the absence of GABA-B(2) subunits.Spasticity therapy reacts to astrocyte GluA1 receptor upregulation following spinal cord injuryPlain radiography in patients treated with intrathecal drug delivery using an implantable pump deviceBaclofen-Induced Encephalopathy in End Stage Renal Disease.Baclofen-induced encephalopathy in patient with end stage renal disease: Two case reports.Oral baclofen administration in persons with chronic spinal cord injury does not prevent the protective effects of spasticity on body composition and glucose homeostasis.Baclofen systemic toxicity: Experimental histopathological and biochemical study.The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial.Direct, long-term intrathecal application of therapeutics to the rodent CNS.Cervical catheter tip placement for intrathecal baclofen administration.Effects of severe spasticity treatment with intrathecal Baclofen in multiple sclerosis patients: Long term follow-up.Surgical management of intractable spasticity.
P2860
Q26862978-977AD3DD-3543-4402-9511-4C5AADE920C6Q27026530-2AF31C2D-A17F-4E99-A506-4179434934DAQ28084723-5D35B2EE-A7A2-4F42-946D-7F5A46DECE52Q30250250-F9E39358-8069-4ACE-B9B0-BCC2958A6488Q33696990-7742575C-3A3E-4C71-B97C-4BEA2256AC09Q33736002-44D05B6A-E88A-4FBC-80EB-A80A40DFAE5AQ33803683-163333CF-D146-4FE9-BF10-96C51DA06437Q34094848-FA773960-3352-4E73-A418-D093CB1106BFQ34203270-70BF3993-D988-4A2C-A74A-A5F1193A071EQ34298312-F60B09EF-A19B-4F4F-AB1F-83498C1F9C96Q34686451-16E38191-40C7-4318-929E-BEC6D1156EE9Q35018491-28F86E85-C211-4D00-8226-2C545C769FEEQ35160555-45EFD8E2-9E22-4915-9DEA-BF36FEA56819Q36056214-C114D420-3C40-48D5-B346-CB025AB0320BQ36339147-AE45ED2A-C35B-43D4-92BE-B999D7B406A2Q36630067-7CF08153-5A22-4D20-99AF-66405C63F982Q36996573-67732DDB-8966-4EF4-9CE7-C6C1C5388223Q37056746-1D0BA08E-4E64-42F9-861E-8ED066C56EB1Q37170208-A6EDE621-3184-49CF-A308-219672D3B49BQ37514645-3DA1A17B-9714-49E5-822C-961369DE7C4BQ37951258-750A0F04-6DD7-44CA-9060-2947D4750A0FQ38115144-8FFB9E35-94F5-4833-9012-E388EB8E5FEEQ38155167-3CD46392-F2CE-4911-B714-FAA675CD7268Q38172116-C8A5A0AA-209C-4DF1-B544-7013F9EAC8B2Q38419942-52D5B4F0-25D8-4EEB-BC88-DC38B3085014Q39909453-5BDA87EA-80F5-4491-A726-4ABFE9C10338Q41150048-24855F53-ADF2-4692-B7E1-FDAAE342F737Q42367718-073660B8-B849-4648-9C15-2DC030407685Q42434327-BE0A62CB-7D03-418C-B440-9CAA49B0A4FBQ42585187-C69E8BA8-51A3-46AB-80EC-550576CB171CQ43290464-F18F709E-4D47-4EC4-A7F1-913CC1BEAEFFQ46737082-9B7DFC3F-B0DD-427C-B5CE-8AC0C23FF78BQ48254878-923B022C-1951-4BA4-A0D5-C23E24B64D0DQ48395041-AFC73726-1A09-4528-9A78-29AEE988B4B4Q51136701-DF48DE62-FE7B-4C82-8A03-F66C4C77BF10Q51381155-D0718E0E-95DC-44B9-96CD-EF5A1BEE859FQ53649794-CC27AFFF-9DA1-4CA9-A7E1-CBD350A66CDE
P2860
A benefit-risk assessment of baclofen in severe spinal spasticity.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
A benefit-risk assessment of baclofen in severe spinal spasticity.
@ast
A benefit-risk assessment of baclofen in severe spinal spasticity.
@en
type
label
A benefit-risk assessment of baclofen in severe spinal spasticity.
@ast
A benefit-risk assessment of baclofen in severe spinal spasticity.
@en
prefLabel
A benefit-risk assessment of baclofen in severe spinal spasticity.
@ast
A benefit-risk assessment of baclofen in severe spinal spasticity.
@en
P1433
P1476
A benefit-risk assessment of baclofen in severe spinal spasticity
@en
P2093
Giustino Tomei
P304
P356
10.2165/00002018-200427110-00004
P50
P577
2004-01-01T00:00:00Z
P6179
1048373790